Recent Updates
Recently added Catalysts

Etoricoxib

Phase 4

Hysterectomy | Small molecule | Pain |Merck & Company, Inc.|Trials Updated: Feb 10, 2017

Etoricoxib development status

Highest phase Phase 4 (NCT00792376)
Phase scored for MRKPhase 3
Registered trials 21 across 8 sponsors since Sep 2004

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLED
Total Trials2
Total Enrollment191

FDA Designations

No designations recorded

Etoricoxib clinical trials

Etoricoxib · 2 trials · 5 indications

Phase 3 1Phase 2 1
NCT00373464Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic SurgeryHysterectomy
COMPLETED126 Analytics
PHASE3COMPLETED
Etoricoxib for Routine Post-operative Pain Prophylaxis in Laparoscopic Surgery
Hysterectomy
NCT00373464126
Unlock trial analytics

Study Endpoints

Primary Endpoints

Equal opioid consumption in both groups postoperatively
Postoperative pain
Within first 5 days after operation
Functional recovery postoperatively
Within first 5 days after operation

Secondary Endpoints

Equal visual analogue scale (VAS) and verbal rating scale (VRS) in the first 4 hours
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
ControlPLACEBO_COMPARATORGiven placebo tablets preoperatively
EtoricoxibACTIVE_COMPARATORGiven etoricoxib preoperatively

Interventions

NameTypeDescription
etoricoxibDRUG -
ControlDRUGGiven placebo
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 70 Years
SexFEMALE
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Patients (American Society of Anaesthesiologists \[ASA\] I and II) due for elective, laparoscopic gynaecologic surgery with the expected need for post-operative opioids: hysterectomy, removal of tube(s) and/or ovarium. * Written informed consent. * Weight between 50 and 120 kg...

Countries:NorwaySingapore
Unlock Eligibility Criteria

Explore more on BiopharmaWatch

Merck & Company, Inc. (MRK)Pipeline, catalysts, financials, insiders and newsBiotech disease mapWho is developing what in each indication, and how crowded it isFDA calendarUpcoming PDUFA dates, AdComs and approval oddsPDUFA calendarEvery scheduled FDA decision date, month by monthHistorical FDA calendarPast decisions and how the stock moved on eachCatalyst SyncUpcoming readouts and decisions, screened by runway and phaseBiotech stock screenerFilter by clinical phase, cash runway and market capDrugs A to ZEvery drug page starting with ECompanies A to ZEvery biotech and pharma company we track